Edition:
United Kingdom

Recipharm AB (publ) (RECIb.ST)

RECIb.ST on Stockholm Stock Exchange

86.75SEK
9:21am GMT
Change (% chg)

-0.25kr (-0.29%)
Prev Close
87.00kr
Open
88.00kr
Day's High
88.00kr
Day's Low
86.25kr
Volume
14,058
Avg. Vol
159,284
52-wk High
131.00kr
52-wk Low
84.00kr

Chart for

About

Recipharm publ AB is a Sweden-based pharmaceutical company, operating as a Contract Development and Manufacturing Organization (CDMO). It is divided in two business areas: Manufacturing Services, supplying a range of pharmaceutical products in different dosage forms, such as solid dose, semi solids, beta-lactams, hormones, dry... (more)

Overall

Beta: 1.59
Market Cap(Mil.): kr4,464.81
Shares Outstanding(Mil.): 47.62
Dividend: 1.50
Yield (%): 1.60

Financials

  Industry Sector
P/E (TTM): -- 31.14 16.44
EPS (TTM): -- -- --
ROI: -- 14.86 10.62
ROE: -- 16.28 14.20

BRIEF-Recipharm commences new supply contract

* RECIPHARM COMMENCES NEW SUPPLY CONTRACT AND COMPLETES PURCHASE OF FACILITY IN SPAIN Source text for Eikon: Further company coverage: (Reporting By Anna Ringstrom)

01 Dec 2017

BRIEF-Recipharm equips a further three facilities for U.S serialisation

* RECIPHARM EQUIPS A FURTHER THREE FACILITIES FOR US SERIALISATION Source text for Eikon: Further company coverage: (Reporting by Stockholm Newsroom)

27 Nov 2017

BRIEF-Recipharm Q3 EBITDA down at SEK ‍103​ mln

* Q3 EBITDA SEK ‍103​ MILLION VERSUS SEK 144 MILLION YEAR AGO

09 Nov 2017

BRIEF-Recipharm to end operations in two facilities in Sweden

* ‍TO START A PROCESS WITH INTENTION OF DISCONTINUING ACTIVITIES BOTH IN STOCKHOLM AND HÖGANÄS.​

09 Nov 2017

BRIEF-Recipharm Q3 EBITDA down at SEK ‍103​ mln

* Q3 NET SALES SEK ‍1.20 BILLION VERSUS SEK 1.14 BILLION YEAR AGO

09 Nov 2017

BRIEF-Recipharm starts cooperation with Roche

* RECIPHARM SIGNS LONG-TERM MANUFACTURING AGREEMENT WITH MAJOR NEW CUSTOMER AND ACQUIRES FACILITY IN SPAIN

20 Sep 2017

BRIEF-Recipharm, Kancera cooperate to manufacture clinical trial supply

* RECIPHARM AND KANCERA COLLABORATE TO MANUFACTURE CLINICAL TRIAL SUPPLY

14 Sep 2017

BRIEF-Recipharm Q2 EBITDA SEK 242 million

* Q2 NET SALES SEK ‍1.40 BILLION VERSUS SEK 1.24 BILLION YEAR AGO​

25 Jul 2017

BRIEF-Recipharm and Lidds establish industrial manufacturing capabilities

* RECIPHARM AND LIDDS ESTABLISH INDUSTRIAL MANUFACTURING CAPABILITIES FOR A NOVEL PROSTATE CANCER PRODUCT Source text for Eikon: Further company coverage: (Gdynia Newsroom)

20 Jul 2017

Earnings vs. Estimates